Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation
JB Rothbard, S Garlington, Q Lin, T Kirschberg… - Nature medicine, 2000 - nature.com
JB Rothbard, S Garlington, Q Lin, T Kirschberg, E Kreider, PL McGrane, PA Wender…
Nature medicine, 2000•nature.comMany systemically effective drugs such as cyclosporin A are ineffective topically because of
their poor penetration into skin. To surmount this problem, we conjugated a heptamer of
arginine to cyclosporin A through a pH-sensitive linker to produce R7–CsA. In contrast to
unmodified cyclosporin A, which fails to penetrate skin, topically applied R7–CsA was
efficiently transported into cells in mouse and human skin. R7–CsA reached dermal T
lymphocytes and inhibited cutaneous inflammation. These data establish a general strategy …
their poor penetration into skin. To surmount this problem, we conjugated a heptamer of
arginine to cyclosporin A through a pH-sensitive linker to produce R7–CsA. In contrast to
unmodified cyclosporin A, which fails to penetrate skin, topically applied R7–CsA was
efficiently transported into cells in mouse and human skin. R7–CsA reached dermal T
lymphocytes and inhibited cutaneous inflammation. These data establish a general strategy …
Abstract
Many systemically effective drugs such as cyclosporin A are ineffective topically because of their poor penetration into skin. To surmount this problem, we conjugated a heptamer of arginine to cyclosporin A through a pH-sensitive linker to produce R7–CsA. In contrast to unmodified cyclosporin A, which fails to penetrate skin, topically applied R7–CsA was efficiently transported into cells in mouse and human skin. R7–CsA reached dermal T lymphocytes and inhibited cutaneous inflammation. These data establish a general strategy for enhancing delivery of poorly absorbed drugs across tissue barriers and provide a new topical approach to the treatment of inflammatory skin disorders.
nature.com